What You Should Know
- The Funding: HEARTio, an artificial intelligence healthcare diagnostics company, has closed $4.25 million in new seed financing. Backers include Intelligence Ventures, Audacious Capital, VU Venture Partners, LifeX, and Bessel.
- The Core Product: HEARTio’s flagship platform, ECGio, utilizes AI to analyze a standard 12-lead electrocardiogram (ECG) to non-invasively predict the presence, severity, and location of coronary artery disease (CAD).
- The Goal: The company will use the fresh capital to launch its pivotal study, which is the critical final step in seeking FDA clearance for the technology.
- The Clinical Validation: The platform is already backed by peer-reviewed rigor. A recent cross-validation study involving over 16,000 patients was published in JACC Advances, alongside a primary validation study in the Canadian Journal of Cardiology.
- The Origin Story: The company was co-founded by Utkars Jain (CEO), Adam Butchy, and Michael Leasure. Jain’s drive to build the company is deeply personal, spurred by the tragic passing of his grandfather due to a chest-pain misdiagnosis.
Finding the Hidden Signals
The premise behind HEARTio’s flagship platform, ECGio, relies on the sheer processing power of deep learning. While a human cardiologist is highly trained to spot arrhythmias or active infarctions on an ECG readout, an AI model can detect microscopic, complex signal patterns that are invisible to the naked eye. HEARTio has trained ECGio through feeding clinical data to the algorithm to translate those subtle electrical signals into a highly accurate prediction of coronary occlusion.
Crucially, the company is proving its claims in the literature before rushing to market. A recent validation study published in JACC Advances cross-validated the AI model on a dataset of over 16,000 patients, proving that the algorithm can perform reliably at scale.
“This successful round of financing is a testament to the momentum we are building in bringing ECGio to market,” said Utkars Jain, Co-founder and CEO of HEARTio. “With this financing, we expect to complete our pivotal study, and submit the technology to the FDA for clearance. Our technology has the potential to democratize cardiovascular care and help create a world where no one experiences a heart attack.”
